COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
复制标题
DOI：
10.1016/s2665-9913(20)30227-7
复制
发表时间：
2020-09-01
影响因子：
25.4
通讯作者：
Dong, Lingli
中科院分区：
文献类型：
--
作者：
Zhong, Jixin;Shen, Guifen;Dong, Lingli
背景在正在进行的新冠肺炎大流行中，风湿病患者对新冠肺炎的易感性尚不清楚。为了解自身免疫性风湿病患者在新冠肺炎暴发期间对新冠肺炎的易感性。方法对中国暴发疫情中心湖北省的自身免疫性风湿病患者进行多中心回顾性研究。通过自动电话调查联系风湿病患者，调查他们对新冠肺炎的易感性。收集了有关接触新冠肺炎或诊断的数据。有记录的新冠肺炎接触史的家庭，即至少有一名家庭成员被诊断出患有新冠肺炎，由医疗专业人员进行跟踪，以获取详细信息，包括性别、年龄、吸烟史、既往病史、药物使用以及与新冠病毒相关的信息。2020年3月20日至3月30日期间，6,228名自身免疫性风湿病患者被纳入研究。在我们的研究人群中，自身免疫性风湿病患者中Covi D-19的总发生率为0“43%(6228例患者中有27例)。我们确定了2019年12月20日至2020年3月20日期间确诊为新冠肺炎的42个家庭，患者要么患有风湿病，要么在疫情爆发期间居住在同一物理地址的家庭成员中。在这42个家系中，43名风湿病患者中有27名(63%)被诊断为新冠肺炎，83名非风湿病患者中有28名(34%)被诊断为新冠肺炎(调整后的优势比[OR]2.68[95%可信区间1.14-6-27]；p=0.023)。服用羟基氯喹的风湿病患者患新冠肺炎感染的风险低于服用其他抗风湿药物的患者(OR0.09[95%CI 0-01-0。94]；p=0。044)。此外，新冠肺炎的风险随着年龄的增长而增加(调整后的OR1.04[95%可信区间1 01-1。解释为自身免疫性风湿病的患者可能比普通人群更容易感染新冠肺炎。资助国家自然资源
Background In the ongoing COVID-19 pandemic, the susceptibility of patients with rheumatic diseases to COVID-19 remains unclear. We aimed to investigate susceptibility to COVID-19 in patients with autoimmune rheumatic diseases during the ongoing COVID-19 pandemic.Methods We did a multicentre retrospective study of patients with autonnmune rheumatic diseases in Hubei province, the epicentre of the COVID-19 outbreak in China. Patients with rheumatic diseases were contacted through an automated telephone-based survey to investigate their susceptibility to COVID-19. Data about COVID-19 exposure or diagnosis were collected. Families with a documented history of COVID-19 exposure, as defined by having at least one family member diagnosed with COVID-19, were followed up by medical professionals to obtain detailed information, including sex, age, smoking history, past medical history, use of medications, and information related to COVID-19.Findings Between March 20 and March 30, 2020, 6228 patients with autoimmune rheumatic diseases were included in the study. The overall rate of COVI D-19 in patients with an autoimmune rheumatic disease in our study population was 0"43% (27 of 6228 patients). We identified 42 families in which COVID-19 was diagnosed between Dec 20, 2019, and March 20, 2020, in either patients with a rheumatic disease or in a family member residing at the same physical address during the outbreak. Within these 42 families, COVID-19 was diagnosed in 27 (63%) of 43 patients with a rheumatic disease and in 28 (34%) of 83 of their family members with no rheumatic disease (adjusted odds ratio [OR] 2.68 [95% CI 1.14-6- 27]; p=0.023). Patients with rheumatic disease who were taking hydroxychloroquine had a lower risk of COVID-19 infection than patients taking other disease-modifying anti-rheumatic drugs (OR 0.09 [95% CI 0- 01-0. 94]; p=0. 044). Additionally, the risk of COVID-19 was increased with age (adjusted OR 1.04 [95% CI 1 01-1. 06]; p=0.0081).Interpretation Patients with autoimmune rheumatic disease might be more susceptible to COVID-19 infection than the general population. Funding National Natural